Clinical trial
An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 4-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B" in Healthy Volunteers
NCT06184269 is registered in ClinicalTrials.gov with Boryung Pharmaceutical Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 4-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B" in Healthy Volunteers
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 23, 2023
- Completion date
- February 18, 2024
- Enrollment
- 58 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
essential hypertension, primary hypercholesterolemia